Impact of residual renal function and HCV seropositivity on plasma CD40/CD40L system and oxidative status in haemodialysis patients

Clinical Biochemistry

Volumn 43, Issue 18, 2010, Pages 1393-1398

  Pawlak, Krystyna ^a   Mysliwiec, Michal ^a   Pawlak, Dariusz ^a,b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b UNIVERSITY OF WARMIA AND MAZURY IN OLSZTYN   (Poland)

Author keywords

Haemodialysis; HCV seropositivity; Oxidative stress; Residual renal function; SCD40; SCD40L

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; COPPER ZINC SUPEROXIDE DISMUTASE; FIBRINOGEN;

ANURIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HEMODIALYSIS PATIENT; HEPATITIS C VIRUS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTIPLE REGRESSION; OXIDATIVE STRESS; PRIORITY JOURNAL; RESIDUAL RENAL FUNCTION;

ADULT; AGED; ANTIGENS, CD40; CD40 LIGAND; FEMALE; HEPACIVIRUS; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; OXIDATION-REDUCTION; OXIDATIVE STRESS; RENAL DIALYSIS; SUPEROXIDE DISMUTASE;

EID: 78149498162     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.09.002     Document Type: Article

References (30)

1. Shemin D., Bostom A.G., Laliberty P., Dworkin L.D. Residual renal function and mortality risk in hemodialysis patients. Am J Kidney Dis 2001, 38:85-90.
2. Termorshuizen F., Dekker F.W., van Manen J.G., Koreavaar J.C., Boeschoten E.W., Krediet R.T. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. J Am Soc Nephrol 2004, 15:1061-1070.
3. Mccarthy J.T., Williams A.W., Johnson W.J. Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function. J Lab Clin Med 1994, 123:495-505.
4. Vilar E., Wellsted D., Chandna S.M., Greenwood R.N., Farrington K. Residual renal function improves outcome in incremental haemodialysis despite reduced dialysis dose. Nephrol Dial Transplant 2009, 24:2502-2510.
5. Stenvinkel P., Pecoits-Filho R., Lindholm B. Coronary artery disease in end-stage renal disease: no longer a simple plumbing problem. J Am Soc Nephrol 2003, 14:1927-1939.
6. Szeto C., Wong T.Y., Chow K., Leung C., Li P.K. Are peritoneal dialysis patients with and without residual renal function equivalent for survival study? Insight from a retrospective review of the cause of death. Nephrol Dial Transplant 2003, 18:977-982.
7. Lusis A.J. Atherosclerosis. Nature 2000, 407:233-241.
8. Young J.L., Libby P., Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002, 88:554-567.
9. Clark L.B., Foy T.M., Noelle R.J. CD40 and its ligand. Adv Immunol 1996, 63:43-78.
10. Henn V., Slupsky J.R., Gräfe M., Anagnostopoulos I., Förster R., Müller-Berghaus G., et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998, 391:591-594.
11. Lim P.-S., Wu M.-Y., Chien S.-W., Wu T-k, Liu C-S, Hu C-Y, et al. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease. Nephrology 2008, 13:677-683.
12. Hocher B., Liefeldt L., Quaschning T., Kalk P., Zlebig R., Godes M., et al. Soluble CD154 is a unique predictor of nonfatal and fatal atherothrombotic events in patients who have end-stage renal disease and are on hemodialysis. J Am Soc Nephrol 2007, 18:1323-1330.
13. Cotin C., Pitard V., Delmas Y., Pelletier N., Defrance T., Moreau J-F, et al. Potential role of soluble CD40 in the humoral immune response impairment of uraemic patients. Immunology 2003, 110:131-140.
14. Schwabe R.F., Engelmann H., Hess S., Fricke H. Soluble CD40 in the serum of healthy donors, patients with chronic renal failure, haemodialysis and chronic ambulatory peritoneal dialysis (CAPD) patients. Clin Exp Immunol 1999, 117:153-158.
15. Pawlak K., Naumnik B., Brzosko S., Pawlak D., Mysliwiec M. Oxidative stress-a link between endothelial injury, coagulation activation and atherosclerosis in haemodialysis patients. Am J Nephrol 2004, 24:154-161.
16. Pawlak K., Pawlak D., Myśliwiec M. Cu/Zn SOD plasma levels as a new useful clinical biomarker of oxidative stress in patients with end-stage renal disease. Clin Biochem 2005, 38:700-705.
17. Tone M., Tone Y., Fairchild P.J., Wykes M., Waldmann H. Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Nat Acad Sci USA 2001, 98:1751-1756.
18. Furuya R., Kumagai H., Odamaki M., Takahashi M., Miyaki A., Hishida A. Impact of residual renal function on plasma levels of advanced oxidation protein products and pentosidine in peritoneal dialysis patients. Nephron Clin Pract 2009, 112:c255-c261.
19. Rizvi M., Pathak D., Freedman J.E., Chacrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med 2008, 14:530-538.
20. Pignatelli P., Sanguigni V., Lenti L., Loffredo L., Carnevale R., Sorge R. Oxidative stress-mediated platelet CD40 ligand upregulation in patients with hypercholesterolemia: effect of atorvastatin. J Thromb Haemost 2007, 5:1170-1178.
21. Pignatelli P., Sanguini V., Paola S.G., Lo Cocco E., Lenti L., Violi F. Vitamin C inhibits platelet expression of CD40 ligand. Free Radic Biol Med 2005, 38:1662-1668.
22. Al Ghumlas A.K., Abdel Gader A.G.M., Al Faleh F.Z. Haemostatic abnormalities in liver disease: could some haemostatic tests be useful as liver function tests?. Blood Coagul Fibrinolysis 2005, 16:329-335.
23. Pawlak K., Pawlak D., Myśliwiec M. Hepatitis intensified oxidative stress, MIP-1β and RANTES plasma levels in uraemic patients. Cytokine 2004, 28:197-204.
24. Pawlak K., Zolbach K., Borawski J., Mysliwlec M., Kovalchuk O., Chyczewski L., et al. Chronic viral hepatitis C, oxidative stress and the coagulation/fibrinolysis system in haemodialysis patients. Thromb Res 2008, 123:166-170.
25. Nascimento M.M., Suliman M.E., Bruchweld A., Hayashi SY, Manfro RC, Qureshi AR, et al. The influence of hepatitis C and iron replacement therapy on plasma pentosidine levels in haemodialysis patients. Nephrol Dial Transplant 2004, 19:3112-3116.
26. Köken T., Serteser M., Kahraman A., Gokce C. Oxidative stress markers in hepatitis C infected hemodialysis patients. J Nephrol 2002, 15:302-307.
27. Schmilovitz-Weiss H., Belinki A., Pappo O., Sulkes J, Melzer E., Kaganovski E., et al. Role of circulating soluble CD40 as an apoptotic marker in liver disease. Apoptosis 2004, 9:205-210.
28. Shiraki K., Sugimoto K., Okano H., Wagayama H., Fujikawa K., Yamanaka T., et al. CD40 expression in HCV-associated chronic liver diseases. Int J Mol Med 2006, 18:559-563.
29. Locatelli F., Buoncristiani U., Canaud B., Kohler H., Petitclere T., Zucchelli P. Dialysis dose and frequency. Nephrol Dial Transplant 2005, 20:285-296.
30. Omoti C.E., Omuemu C.E., Olu-Eddo A.N. The reological profile of chronic liver disease patients in Nigeria. Clin Hemorheol Microcirc 2009, 42:279-284.